A Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity

Simple item page
dc.contributor.authorCorrea-Burrows, Paulina
dc.contributor.authorMatamoros, Mariela
dc.contributor.authorde Toro, Valeria
dc.contributor.authorZepeda, Diego
dc.contributor.authorArriaza, Marta
dc.contributor.authorBurrows, Raquel
dc.date.accessioned2025-01-20T20:18:03Z
dc.date.available2025-01-20T20:18:03Z
dc.date.issued2023
dc.description.abstractBackgroundThe Single-Point Insulin Sensitivity Estimator (SPISE) is a biomarker of insulin sensitivity estimated using BMI and triglycerides and high-density lipoprotein cholesterol. We assessed the accuracy of SPISE to screen obesity-related cardiometabolic risk in children and adolescents. MethodCross-sectional validation study for a screening test in a sample of n=725 children and adolescents from an obesity clinic. Weight, height, waist circumference, blood arterial pressure, lipid profile, glucose, insulin and Tanner stage were measured. BMI, BMI for-age-and sex (BAZ), and HOMA-IR were estimated. HOMA-IR values >= 2.1 and >= 3.3 were considered IR in Tanner I-II, >= 3.3 for Tanner III-IV and >= 2.6 for Tanner V, respectively. Metabolic Syndrome (MetS) was diagnosed with the Cook phenotype. SPISE was estimated according to the following algorithm: [600* HDL boolean AND 0.185/(TG boolean AND 0.2* BMI boolean AND 1.338)]. The optimal SPISE cut points for IR and MetS prediction were determined by ROC curve analysis. ResultsIn prepubertal obese patients (9.2 +/- 2.1y; 18.4% males), the prevalence of IR and MetS was 28.2% y 46.9%, respectively; 58% had severe obesity (BAZ >= 4 SD). In pubertal obese patients (12.6 +/- 1.8y; 57% males), the prevalence of IR and MetS was 34.1% and 55.3%, respectively; 34% had severe obesity. In prepubertal children, a SPISE of 6.3 showed the highest sensitivity (73.2%) and specificity (80%) to screen individuals with IR (AUC: 0.80; LR +: 3.3). Likewise, a SPISE of 5.7 got the highest sensitivity (82.6%) and specificity (86.1%) to screen patients with MetS (AUC: 0.87; LR +: 5.4). In pubertal patients, a SPISE of 5.4 showed the highest sensitivity and specificity to screen children and adolescents with both IR (Sn: 76.1%; Sp: 77.5%; AUC: 0.8; LR +: 3.1) and MetS (Sn: 90.4%; Sp: 76.1%; AUC: 0.90; LR +: 3.5). ConclusionIn children and adolescents with obesity, SPISE has good or very good performance in predicting IR and MetS. SPISE may be considered a relatively simple and low-cost diagnosis tool that can be helpful to identify patients with greater biological risk. In adolescents with obesity, the same cut point allows identification of those at higher risk of both IR and MetS.
dc.fuente.origenWOS
dc.identifier.doi10.3389/fendo.2023.1078949
dc.identifier.issn1664-2392
dc.identifier.urihttps://doi.org/10.3389/fendo.2023.1078949
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/92438
dc.identifier.wosidWOS:000935895400001
dc.language.isoen
dc.revistaFrontiers in endocrinology
dc.rightsacceso restringido
dc.subjectSingle-Point Insulin Sensitivity Estimator
dc.subjectpediatric obesity
dc.subjectinsulin resistance
dc.subjectmetabolic syndrome
dc.subjectcardiometabolic risk
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA Single-Point Insulin Sensitivity Estimator (SPISE) of 5.4 is a good predictor of both metabolic syndrome and insulin resistance in adolescents with obesity
dc.typeartículo
dc.volumen14
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas